The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

Invesco S&P 500 Pure Value ETF offers low valuations, but underperforms peers due to high volatility and expenses. Read what ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

We recently published a list of 12 Best Safe Dividend Stocks for 2025. In this article, we are going to take a look at where ...

A young local startup offering virtual appointments for patients at risk for dementia and cognitive decline is getting ready ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

Salem Health and Regence BlueCross BlueShield of Oregon are returning to the negotiating table after almost 30,000 people ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...